Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Modulation of Human Thrombopoietin Receptor Conformations Uncouples JAK2 V617F-Driven From Cytokine-Induced Activation.

Papadopoulos N. et al, (2023), Blood

Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers.

Defour J-P. et al, (2023), eLife, 12

Senescence-related impairment of autophagy induces toxic intraneuronal amyloid-β accumulation in a mouse model of amyloid pathology.

Suelves N. et al, (2023), Acta neuropathologica communications, 11

Oncogenic CALR mutant C-terminus mediates dual binding to the thrombopoietin receptor triggering complex dimerization and activation.

Papadopoulos N. et al, (2023), Nature communications, 14

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.

Matuozzo D. et al, (2023), Genome medicine, 15

SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.

Willekens C. et al, (2023), Leukemia

Innovations 2022 in the field of hemostasis-thrombosis

Bailly S. et al, (2023), Louvain Medical, 142, 101 - 108

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.

Pecquet C. et al, (2023), Blood, 141, 917 - 929

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis.

Lecomte S. et al, (2023), Blood, 141, 490 - 502

Editorial: Recent advances in molecular and structural endocrinology.

De Meyts P. and Constantinescu SN., (2023), Frontiers in endocrinology, 14

Leukemic conversion involving RAS mutations of type 1 CALR-mutated primary myelofibrosis in a patient treated for HCV cirrhosis: a case report.

Gurban P. et al, (2023), Frontiers in oncology, 13

Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?

Havelange V. and Constantinescu SN., (2023), American Journal of Hematology

Structural Determinant of β-Amyloid Formation: From Transmembrane Protein Dimerization to β-Amyloid Aggregates.

Papadopoulos N. et al, (2022), Biomedicines, 10

The 2 faces of ERK2 in MPNs.

Havelange V. and Constantinescu SN., (2022), Blood, 140, 298 - 300

Studying severe long COVID to understand post-infectious disorders beyond COVID-19.

Brodin P. et al, (2022), Nature medicine, 28, 879 - 882

JAK inhibitors and COVID-19.

Levy G. et al, (2022), Journal for immunotherapy of cancer, 10

2021 Innovation in hematology

Vekemans MC. et al, (2022), Louvain Medical, 141, 85 - 102

Human genetic and immunological determinants of critical COVID-19 pneumonia

Zhang Q. et al, (2022), Nature

Degrading JAK2 in ALL by ruxolitinib-based PROTACs

Constantinescu SN. and Pecquet C., (2021), Blood, 138, 2301 - 2302

MPL S505C enhances driver mutations at W515 in essential thrombocythemia.

Varghese LN. et al, (2021), Blood cancer journal, 11

Load More

Include forthcoming?